Two distinguished University of Arizona professors and innovators have been named as National Academy of Inventors Fellows. Thomas Koch, professor and dean of the College of Optical Sciences, and Harrison Barrett, Regents’ Professor of medical imaging, optical sciences and applied mathematics, will now join a growing cadre of distinguished fellows from the UA.

When a person is paralyzed by a stroke or an injury, the brain and the neuron networks that control movement become disconnected from the muscles. Dr. Andrew Fuglevand is using artificial intelligence to stimulate multiple muscles to elicit natural movement in ways previous methods have been unable to do.

Victoria Murrain, DO, has been promoted from interim to permanent deputy dean for diversity and inclusion at the University of Arizona College of Medicine – Tucson.

Pharmacogenetics expert, Jason Hansen Karnes, PharmD, PhD, BCPS, FAHA, has been named director of scientific programs for the All of Us Research Program team at the University of Arizona and Banner Health.

Led by Roberta Brinton, PhD, the Center for Innovation in Brain Science at the University of Arizona Health Sciences has received one of seven research grants awarded by WAM to leading scientific institutions. The grant will allow the Center to continue its WAM-funded research begun in 2016, and to discover critical information about the long-term impact of hormone interventions on women’s risk of developing Alzheimer's disease.

UA Cancer Center opens clinical trial in Greater Phoenix for novel liver cancer treatment.

A research team led by Jared Churko, PhD, director of the University of Arizona iPSC Core in the UA Sarver Heart Center, used a transcriptomic approach — studying what genes are expressed — to identify gene signatures of cell subpopulations identified as atrial-like or ventricular-like. This understanding could lead to regenerative therapy discoveries for the millions of people living with damaged heart muscle caused by heart attacks or other chronic heart conditions.

University of Arizona scientists hope they have made progress toward a next-generation drug that may slow tumor growth and boost radiation’s effectiveness in patients with the deadly brain cancer.

Michael Kruer, MD, receives the first federally funded grant to research genetic causes of condition that affects 1 in 250 children.

Individuals with a particular genetic factor may be more resistant to plaque build-up and have a reduced risk for coronary artery disease.